Literature DB >> 25444822

Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI.

Kimberly D Brewer1, Kerry Lake2, Nicole Pelot2, Marianne M Stanford3, Drew R DeBay2, Andrea Penwell4, Genevieve M Weir3, Mohan Karkada3, Marc Mansour4, Chris V Bowen5.   

Abstract

Immunotherapies, including peptide-based vaccines, are a growing area of cancer research, and understanding their mechanism of action is crucial for their continued development and clinical application. Exploring the biodistribution of vaccine components may be key to understanding this action. This work used magnetic resonance imaging (MRI) to characterize the in vivo biodistribution of the antigen and oil substrate of the vaccine delivery system known as DepoVax(TM). DepoVax uses a novel adjuvanted lipid-in-oil based formulation to solubilise antigens and promote a depot effect. In this study, antigen or oil were tagged with superparamagnetic iron oxide (SPIO), making them visible on MR images. This enables tracking of individual vaccine components to determine changes in biodistribution. Mice were injected with SPIO-labeled antigen or SPIO-labeled oil, and imaged to examine clearance of labeled components from the vaccine site. The SPIO-antigen was steadily cleared, with nearly half cleared within two months post-vaccination. In contrast, the SPIO-oil remained relatively unchanged. The biodistribution of the SPIO-antigen component within the vaccine site was heterogeneous, indicating the presence of active clearance mechanisms, rather than passive diffusion or drainage. Mice injected with SPIO-antigen also showed MRI contrast for several weeks post-vaccination in the draining inguinal lymph node. These results indicate that MRI can visualize the in vivo longitudinal biodistribution of vaccine components. The sustained clearance is consistent with antigen up-take and trafficking by immune cells, leading to accumulation in the draining lymph node, which corresponds to the sustained immune responses and reduced tumor burden observed in vaccinated mice.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; HPV-16; MRI; Superparamagnetic iron oxide (SPIO); Vaccines

Mesh:

Substances:

Year:  2014        PMID: 25444822     DOI: 10.1016/j.vaccine.2014.10.058

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.

Authors:  Neil L Berinstein; Mohan Karkada; Amit M Oza; Kunle Odunsi; Jeannine A Villella; John J Nemunaitis; Michael A Morse; Tanja Pejovic; James Bentley; Marc Buyse; Rita Nigam; Genevieve M Weir; Lisa D MacDonald; Tara Quinton; Rajkannan Rajagopalan; Kendall Sharp; Andrea Penwell; Leeladhar Sammatur; Tomasz Burzykowski; Marianne M Stanford; Marc Mansour
Journal:  Oncoimmunology       Date:  2015-05-07       Impact factor: 8.110

2.  Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.

Authors:  Genevieve M Weir; Olga Hrytsenko; Tara Quinton; Neil L Berinstein; Marianne M Stanford; Marc Mansour
Journal:  J Immunother Cancer       Date:  2016-10-18       Impact factor: 13.751

3.  Using lymph node swelling as a potential biomarker for successful vaccination.

Authors:  Kimberly D Brewer; Drew R DeBay; Iulia Dude; Christa Davis; Kerry Lake; Cathryn Parsons; Rajkannan Rajagopalan; Genevieve Weir; Marianne M Stanford; Marc Mansour; Chris V Bowen
Journal:  Oncotarget       Date:  2016-06-14

4.  Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform.

Authors:  Lisa D MacDonald; Alecia MacKay; Valarmathy Kaliaperumal; Genevieve Weir; Andrea Penwell; Rajkannan Rajagopalan; Joanne M Langley; Scott Halperin; Marc Mansour; Marianne M Stanford
Journal:  Hum Vaccin Immunother       Date:  2017-10-30       Impact factor: 3.452

5.  Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo.

Authors:  Genevieve M Weir; Mohan Karkada; David Hoskin; Marianne M Stanford; Lisa MacDonald; Marc Mansour; Robert S Liwski
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

Review 6.  Predictive Markers of Immunogenicity and Efficacy for Human Vaccines.

Authors:  Matthieu Van Tilbeurgh; Katia Lemdani; Anne-Sophie Beignon; Catherine Chapon; Nicolas Tchitchek; Lina Cheraitia; Ernesto Marcos Lopez; Quentin Pascal; Roger Le Grand; Pauline Maisonnasse; Caroline Manet
Journal:  Vaccines (Basel)       Date:  2021-06-01

7.  Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines.

Authors:  Drew R DeBay; Kimberly D Brewer; Sarah A LeBlanc; Genevieve M Weir; Marianne M Stanford; Marc Mansour; Chris V Bowen
Journal:  Mol Ther Methods Clin Dev       Date:  2015-12-16       Impact factor: 6.698

8.  Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control.

Authors:  Kimberly D Brewer; Genevieve M Weir; Iulia Dude; Christa Davis; Cathryn Parsons; Andrea Penwell; Rajkannan Rajagopalan; Leeladhar Sammatur; Chris V Bowen; Marianne M Stanford
Journal:  J Biomed Sci       Date:  2018-01-27       Impact factor: 8.410

9.  A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study.

Authors:  Joanne M Langley; Lisa D MacDonald; Genevieve M Weir; Donna MacKinnon-Cameron; Lingyun Ye; Shelly McNeil; Bert Schepens; Xavier Saelens; Marianne M Stanford; Scott A Halperin
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

10.  Generation of highly activated, antigen-specific tumor-infiltrating CD8+ T cells induced by a novel T cell-targeted immunotherapy.

Authors:  Ava Vila-Leahey; Alecia MacKay; Liliana Portales-Cervantes; Genevieve M Weir; Alexandra Merkx-Jacques; Marianne M Stanford
Journal:  Oncoimmunology       Date:  2020-06-27       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.